MedTrace Logo

Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV

NCT06959563 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-05-20

No results posted yet for this study

Summary

Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients.

1. Treat Infection of Multiple HPV Virus Strains via Trained Immunity.
2. Activate human HPV Antigen Presentation Reaction.
3. The human antigen presenting cells (APCs) can treat the HPV virus protein antigens into small peptide fragments, and then clear HPV virus in vivo.

Conditions

Interventions

BIOLOGICAL

9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use

By the percutaneous route with the multiple puncture device - 9vHPV Vaccine 1.0 mL plus BCG Organism 50 MG Mix

Sponsors & Collaborators

  • UnitedHealthcare

    collaborator OTHER

  • Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

    lead INDUSTRY

Principal Investigators

  • Han ID Xu, MD/PhD/FAPCR · Medicine Invention Design Incorporation

  • Han Xu, MD/PhD/FAPCR · Medicine Invention Design Incorporation

  • Han Xu, MD/PhD/FAPCR · Medicine Invention Design Incorporation

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
24 Years
Max Age
64 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-28
Primary Completion
2026-10-18
Completion
2026-10-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06959563 on ClinicalTrials.gov